Relaterat / Kontaktpersoner
Relaterat / Nyheter
Scandinavian Biopharma officially starts their late phase development program in Africa funded by EDCTP
Pressmeddelanden • Apr 18, 2019 12:26 CEST
This trial will establish the exact safe and immunogenic dose of the vaccine in young children (6-23 months of age) as well as to explore the potential benefits of a third booster dose. The study will be initiated in healthy adults and followed by young children (6-23 months of age) in Zambia starting from May 2019.